Today begins the Phase 2/3 part of our continuous study of the Pfizer - @BioNTech #COVID19 vaccine in healthy children. This is the next step allowing us to gather data to understand the safety and immunogenicity of the vaccine in this group aged 5–11 years.

— Pfizer Inc. (@pfizer) June 8, 2021